These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 33704360)

  • 1. NCX 667, a Novel Nitric Oxide Donor, Lowers Intraocular Pressure in Rabbits, Dogs, and Non-Human Primates and Enhances TGFβ2-Induced Outflow in HTM/HSC Constructs.
    Bastia E; Toris CB; Brambilla S; Galli C; Almirante N; Bergamini MVW; Masini E; Sgambellone S; Unser AM; Ahmed F; Torrejon KY; Navratil T; Impagnatiello F
    Invest Ophthalmol Vis Sci; 2021 Mar; 62(3):17. PubMed ID: 33704360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraocular Pressure-Lowering Activity of NCX 470, a Novel Nitric Oxide-Donating Bimatoprost in Preclinical Models.
    Impagnatiello F; Toris CB; Batugo M; Prasanna G; Borghi V; Bastia E; Ongini E; Krauss AH
    Invest Ophthalmol Vis Sci; 2015 Oct; 56(11):6558-64. PubMed ID: 26457541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NCX 470 Reduces Intraocular Pressure More Effectively Than Lumigan in Dogs and Enhances Conventional and Uveoscleral Outflow in Non-Human Primates and Human Trabecular Meshwork/Schlemm's Canal Constructs.
    Galli C; Bastia E; Hubatsch DA; Toris C; Fan S; Unser A; Ahmed F; Torrejon KY; Impagnatiello F
    J Ocul Pharmacol Ther; 2024; 40(6):389-396. PubMed ID: 38088745
    [No Abstract]   [Full Text] [Related]  

  • 4. Nanoencapsulated hybrid compound SA-2 with long-lasting intraocular pressure-lowering activity in rodent eyes.
    Stankowska DL; Millar JC; Kodati B; Behera S; Chaphalkar RM; Nguyen T; Nguyen KT; Krishnamoorthy RR; Ellis DZ; Acharya S
    Mol Vis; 2021; 27():37-49. PubMed ID: 33633438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NCX 1741, a Novel Nitric Oxide-Donating Phosphodiesterase-5 Inhibitor, Exerts Rapid and Long-Lasting Intraocular Pressure-Lowering in Cynomolgus Monkeys.
    Bastia E; Toris C; Bukowski JM; Brambilla S; Galli C; Almirante N; Bergamini MVW; Lucarini L; Navratil T; Impagnatiello F
    J Ocul Pharmacol Ther; 2021 May; 37(4):215-222. PubMed ID: 33595367
    [No Abstract]   [Full Text] [Related]  

  • 6. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models.
    Krauss AH; Impagnatiello F; Toris CB; Gale DC; Prasanna G; Borghi V; Chiroli V; Chong WK; Carreiro ST; Ongini E
    Exp Eye Res; 2011 Sep; 93(3):250-5. PubMed ID: 21396362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma.
    Borghi V; Bastia E; Guzzetta M; Chiroli V; Toris CB; Batugo MR; Carreiro ST; Chong WK; Gale DC; Kucera DJ; Jia L; Prasanna G; Ongini E; Krauss AH; Impagnatiello F
    J Ocul Pharmacol Ther; 2010 Apr; 26(2):125-32. PubMed ID: 20415621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A digoxin derivative that potently reduces intraocular pressure: efficacy and mechanism of action in different animal models.
    Barathi VA; Katz A; Chaudhary S; Li HL; Tal DM; Marcovich A; Do CW; Karlish SJD
    Am J Physiol Cell Physiol; 2024 May; 326(5):C1505-C1519. PubMed ID: 38557355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ID1 and ID3 are Negative Regulators of TGFβ2-Induced Ocular Hypertension and Compromised Aqueous Humor Outflow Facility in Mice.
    Mody AA; Millar JC; Clark AF
    Invest Ophthalmol Vis Sci; 2021 May; 62(6):3. PubMed ID: 33938911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of topical TGF-β1, TGF-β2, ATX, and LPA on IOP elevation and regulation of the conventional aqueous humor outflow pathway.
    Nakamura N; Yamagishi R; Honjo M; Igarashi N; Shimizu S; Aihara M
    Mol Vis; 2021; 27():61-77. PubMed ID: 33633440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dual acting compound with latanoprost amide and nitric oxide releasing properties, shows ocular hypotensive effects in rabbits and dogs.
    Impagnatiello F; Borghi V; Gale DC; Batugo M; Guzzetta M; Brambilla S; Carreiro ST; Chong WK; Prasanna G; Chiroli V; Ongini E; Krauss AH
    Exp Eye Res; 2011 Sep; 93(3):243-9. PubMed ID: 21356209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing.
    Prasanna G; Ferrara L; Adams C; Ehara T; Li B; Yang L; Xiang C; Ng CTH; Kim S; Towler C; Topley T; McAllister C; Ghosh M; Newton R; Stacy R; Rice DS; Mogi M
    Invest Ophthalmol Vis Sci; 2018 Apr; 59(5):1704-1716. PubMed ID: 29610853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes.
    Sharif NA; McLaughlin MA; Kelly CR; Katoli P; Drace C; Husain S; Crosson C; Toris C; Zhan GL; Camras C
    Exp Eye Res; 2009 Mar; 88(3):386-97. PubMed ID: 18992242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and intraocular pressure-lowering activity of TAK-639, a novel C-type natriuretic peptide analog, in rabbit, dog, and monkey.
    Savinainen A; Prusakiewicz JJ; Oswald J; Spencer E; Lou Z; Cohen ML; Rashidzadeh H; Josiah S
    Exp Eye Res; 2019 Dec; 189():107836. PubMed ID: 31626797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Netarsudil Improves Trabecular Outflow Facility in Patients with Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 2 Study.
    Sit AJ; Gupta D; Kazemi A; McKee H; Challa P; Liu KC; Lopez J; Kopczynski C; Heah T
    Am J Ophthalmol; 2021 Jun; 226():262-269. PubMed ID: 33524367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies.
    Cavet ME; DeCory HH
    J Ocul Pharmacol Ther; 2018; 34(1-2):52-60. PubMed ID: 28783422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of TAK-639, a novel topical C-type natriuretic peptide analog, on intraocular pressure and aqueous humor dynamics in mice.
    Millar JC; Savinainen A; Josiah S; Pang IH
    Exp Eye Res; 2019 Nov; 188():107763. PubMed ID: 31421135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human experience and efficacy of omidenepag isopropyl (Eybelis®; Omlonti®): Discovery to approval of the novel non-prostaglandin EP2-receptor-selective agonist ocular hypotensive drug.
    Sharif NA
    Curr Opin Pharmacol; 2024 Feb; 74():102426. PubMed ID: 38168596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey.
    Nilsson SF; Drecoll E; Lütjen-Drecoll E; Toris CB; Krauss AH; Kharlamb A; Nieves A; Guerra T; Woodward DF
    Invest Ophthalmol Vis Sci; 2006 Sep; 47(9):4042-9. PubMed ID: 16936121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Toll-Like Receptor 4 Inhibition on Transforming Growth Factor-β2 Signaling in the Human Trabecular Meshwork.
    Sharma TP; Curry S; McDowell CM
    J Ocul Pharmacol Ther; 2020 Apr; 36(3):170-178. PubMed ID: 31834824
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.